ECO Animal Health - HY Results - Investor Presentation video - 29 November 2023

The management discussed their 9% revenue growth, despite currencies headwinds for a large part of the first half, and strong visibility over second half revenue. The team talked about their expectation of H2 gross margin improvement, the new Aivlosin® claim approved in the US & Canada, and the exciting prospects for their R&D pipeline as highlighted in the recent Capital Markets Day. They also explored the topic of M&A and the opportunities for both product and regional bolt-ons. Management answered a wide range of questions asked by viewers.

ECO Animal Health Group (AIM: EAH) is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, Interim Results were for the period to 30th September 2023 and presented by David Hallas (CEO) and Chris Wilks (CFO).

The full video has been divided into chapters, as below:
0:00:00 Introduction and Strategy
0:01:30 Highlights
0:05:15 Revenues
0:10:06 Expenditures
0:12:36 Gross margin & EBITDA comments
0:19:10 ESG Summary
0:20:24 Balance sheet & cashflow
0:23:04 First approvals
0:26:05 Conclusion & Outlook
0:28:00 Questions & Answers